ClinicalTrials.gg
RecruitingNCT07314047PARTNERUpdated Jan 2, 2026

The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

An interventional study of liquid embolic agent in Brain Arteriovenous Malformation and Arteriovenous Fistula, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2024, registered Jan 2025).
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.

Planned enrollment
10th of 14
116 · median 184
Started
2024
with 3 others
No phase
13 of 20
4 open now
Registered
17th of 20
by date

Among the 20 studies in Arteriovenous Fistula with a site in China, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2024, is one of 13 with no phase, and was the 17th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arteriovenous Fistula with a site in China, or all of them as a file.
02

Study summary

This study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion and exclusion criteria specified in this trial protocol, approximately 116 subjects with brain arteriovenous malformation will be enrolled for interventional embolization treatment. The subjects will undergo follow-up before the surgery, after device implantation, at discharge, 1 month (± 7 days), 6 months (± 30 days), and 12 months (± 60 days) after the first embolization. When necessary, unscheduled follow-up will be conducted to record various indicators for evaluating the safety and effectiveness of liquid embolic agents in the treatment of brain arteriovenous malformations.

03

Conditions studied

  • Brain Arteriovenous Malformation
  • Arteriovenous Fistula

Browse trials for

Keywords

  • brain arteriovenous malformation
  • arteriovenous fistula
  • LIQUID EMBOLIC AGENT
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 80 years at the time of signing the
  • Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA
  • The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ \~ Ⅳ
  • Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form
  • Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Multiple brain arteriovenous malformations
  • Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period
  • Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years
  • Brain arteriovenous malformation with bleeding within 1 week
  • Brain arteriovenous malformation with an expected number of embolizations ≥ 4
  • Brain arteriovenous malformation scheduled for surgical resection after embolization
  • mRS score ≥ 3
  • Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc
  • Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.) within 30 days prior to signing the form, or those scheduled for such procedures within 60 days after signing the informed consent form
  • for liquid embolic agent treatment, including but not limited to: contraindications for DSA, severe allergy or intolerance to contrast agents, severe allergy or intolerance to antiplatelet or anticoagulant medications required for treatment, or severe allergy to tantalum metal
  • Pregnant or lactating women
  • Subjects participating in other drug or device studies that have not reached their endpoints or who have just withdrawn from the group for less than one month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Liquid embolic agent

    Liquid embolic agent developed and manufactured by MicroPort NeuroTech.Liquid embolic agents are used to embolize cerebrovascular malformations during the procedure.

    Device: liquid embolic agent

  • Active comparator
    the Onyx Liquid Embolic System

    The Onyx Liquid Embolic System was developed and manufactured by Micro Therapeutics Inc. DBA ev3 Neurovascular. The Onyx Liquid Embolic System is used to embolize cerebrovascular malformations during the procedure.

    Device: liquid embolic agent

Interventions

  • Deviceliquid embolic agent

    liquid embolic agent

06

What researchers measure

Primary outcomes

  1. Rate of effective embolization of target brain arteriovenous malformation

    Effective embolization refers to a reduction of ≥ 50% after the last embolization of the target brain arteriovenous malformation compared with that before the first embolization

    Time frame: Perioperative

Secondary outcomes

  1. Rate of favorable clinical outcomes during the 1 year follow-up period

    Favorable clinical outcome refers to a mRS score of ≥ 0 and ≤ 2

    Time frame: 1 year after procedure

  2. Incidence of symptomatic stroke or death within one month after procedure

    Time frame: 1 month after procedure

  3. Incidence of symptomatic intracranial hemorrhage related to procedure within 1 month after procedure

    Time frame: 1 month after procedure

  4. Incidence of symptomatic ischemic stroke related to procedure within 1 month after procedure

    Time frame: 1 month after procedure

  5. Incidence of device-related serious adverse events during the 1 year follow-up period

    Time frame: 1 year after procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — To be decided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in May 2025, 12 months.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 2, 2026
StartActual
May 28, 2024
Primary completionActual
May 28, 2025
CompletionEst.
May 28, 2026
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07314047
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
May 28, 2024
Primary completion
May 28, 2025
Completion
May 28, 2026 (estimated)
Last update
Jan 2, 2026

Study contacts

Liu Shugen
Contact
Shugen.Liu@microport.com
18353892888

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion